Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK sets out further steps to address emerging global health security challenges
GSK will set out a series of steps to further address emerging global health challenges
Read more -
GSK’s candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
GSK on track to file regulatory applications in 2016
Read more -
GSK announces EU regulatory submission for sirukumab in rheumatoid arthritis
Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland...
Read more -
GSK divests non-core assets to Aspen
A series of agreements Between Aspen and GSK through focusing on core therapeutic areas
Read more -
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress
Improvements in lung function and health-related quality of life supported by statistically signi...
Read more -
‘Real world’ data shows 83 percent effectiveness for Bexsero® in infants in first year of UK national meningitis B immunisation programme
Cases of meningitis B halved after ten months
Read more -
GSK announce positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress
The results from the pioneering Salford Lung Study (SLS) have been published in the New England J...
Read more -
NEJM publishes results of GSK’s long-term LABA safety study of Advair® Diskus® in children aged 4-11 years with asthma
Headline results reported in March, demonstrated that the study had achieved its primary endpoint.
Read more -
GSK’s continued commitment to innovative respiratory research demonstrated in European Respiratory Society congress data presentations
More than 30 abstracts from the company will be featured at the meeting.
Read more -
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment
HIV care is a long-term prospect for those living with the disease, requiring life-long adherence...
Read more -
GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines
GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.
Read more -
Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016
GSK delivers further progress against strategy with strong Q2 performance
Read more -
GSK in-licenses anti-IL-33R monoclonal antibody for severe asthma from Janssen
Agreement further strengthens respiratory pipeline of targeted biological therapies
Read more -
GSK announces significant new investment in UK manufacturing network
GSK today announced £275 million of new investments at three of its manufacturing sites in the UK...
Read more -
ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV
ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, mult...
Read more -
GSK and Save the Children call for developing country innovations to enter $1 million award
GSK and Save the Children today launched their fourth annual $1 million Healthcare Innovation Award.
Read more -
Update on GSK’s response to the Zika virus disease outbreak
Since the outbreak of Zika virus disease began in the Americas late last year, GSK has been asses...
Read more -
GSK announces start of phase I oncology study with its ICOS agonist antibody
The start of a phase I clinical trial with GSK3359609, an investigational inducibile T-cell costi...
Read more -
FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients
FULFIL - Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy
Read more -
Executive Director Change
Dr Moncef Slaoui, Chairman, Vaccines, has indicated to the Board his intention to retire from the...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
